CA-TIGO
Tigo Energy, Inc. (NASDAQ: TYGO), a leading provider of intelligent solar and energy software solutions, today announced it will unveil the new Tigo Installer Loyalty Program for residential PV installers in EMEA at Intersolar Europe 2024. As sustainable energy sources comprised 30% of all energy generated globally in 2023, with solar becoming an increasingly large contributor to that output, Tigo Energy is committed to supporting and invigorating the solar industry through initiatives like this loyalty program. Through exclusive benefits and solutions, the Tigo Installer Loyalty Program will recognize the dedication and professionalism of installers who choose Tigo solutions, further supporting their continued success and emphasizing the vitality of all members of the solar value chain to ensure the health of the solar industry.
Intersolar Europe 2024 attendees are invited to learn more about the training requirements and other qualifications for the Tigo Installer Loyalty Program by attending one of the scheduled program overview presentations. A comprehensive calendar of these introductory sessions is available on this page. Tigo will also offer the opportunity to enroll in the program at the event.
“We have worked with Tigo for years, and we are delighted to see this initiative come to installers here in the EMEA region,” said Michael Schmittinger, Managing Director at MMS Communication GmbH & Co. KG. “Our technicians and system designers have gained much from the Tigo Academy training resources, so I am happy to see this platform continue to be a focus in the loyalty program. We look forward to getting involved, learning, contributing, and continuing to build our solar business.”
“As the solar industry converges on Intersolar Europe in Munich, we are excited to welcome PV professionals into our new Installer Loyalty Program, introduce our latest MLPE products, and showcase the power of Tigo software to enhance system performance,” said Mirko Bindi, Senior VP Sales EMEA & MD Europe at Tigo Energy. “At Tigo, we are building the technology and service-oriented culture to empower all solar installers to embrace continuous improvement and a dedication to quality across the entire solar value chain. Underpinning these initiatives is a constantly evolving set of software capabilities that are quickly becoming the catalyst to achieving these goals, and we are very excited to showcase all of this at Intersolar Europe this year.”
With three tiers of participation, the Tigo Installer Loyalty Program offers progressively more valuable benefits for participants, including co-branding, homeowner sales leads, customized collateral, and promotion via the Tigo newsletter. Program participants will also be able to gain early access to new product developments, including participation in Tigo installer council sessions to provide the Company feedback. In addition to the new loyalty program, Tigo will showcase the Tigo EI Residential Solution, now extended to e-mobility with the GO EV Charger. The Company will also showcase the recently-released TS4-X, a new family of Flex MLPE solutions for high-power solar modules, providing safety, monitoring, optimization, and a new Multi-Factor Rapid Shutdown (MFRS) capability for energy-critical applications. Remaining true to the Company’s commitment to open architectures and broad compatibility, products within the TS4-X family work with the largest selection of third-party inverters, supporting the latest high-power and bifacial solar modules, up to 800W.
“We have carried Tigo products in our portfolio for more than ten years, and the new high-power TS4-X optimizers are an outstanding addition to our product range,” said Justin Gann, marketing manager for products and suppliers at Krannich Group GmbH. “We will exhibit the entire range of Tigo solutions at Intersolar this year because these products have proven to be very reliable and of high quality, and they are becoming increasingly popular with our customers. We are delighted to have a high-quality professional provider like Tigo in our portfolio.”
Additionally, Tigo will hold two Technical Coffee Breaks, during which solar professionals can review the specifications of the new TS4-X product family and the EI Residential Solution with members of the Tigo product team. Participation in the Technical Coffee Breaks is free, and the sessions will be held on June 19th and 20th at 16:00 at the Tigo booth (#B4.239).
Please visit the scheduling page here to view a complete list of partners displaying Tigo solutions, register for an Installer Loyalty Program presentation, or schedule a meeting with a member of the Tigo team. To inquire about the Installer Loyalty Program, visit here.
About Tigo Energy
Founded in 2007, Tigo is a worldwide leader in the development and manufacture of smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Tigo combines its Flex MLPE (Module Level Power Electronics) and solar optimizer technology with intelligent, cloud-based software capabilities for advanced energy monitoring and control. Tigo MLPE products maximize performance, enable real-time energy monitoring, and provide code-required rapid shutdown at the module level. The company also develops and manufactures products such as inverters and battery storage systems for the residential solar-plus-storage market. For more information, please visit www.tigoenergy.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240610982934/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom